Bogart Wealth LLC Sells 7,101 Shares of Danaher Corporation (NYSE:DHR)

Bogart Wealth LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 18.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,447 shares of the conglomerate's stock after selling 7,101 shares during the quarter. Bogart Wealth LLC's holdings in Danaher were worth $6,242,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in DHR. Norges Bank purchased a new position in shares of Danaher in the fourth quarter worth $2,130,740,000. GAMMA Investing LLC raised its position in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after buying an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after acquiring an additional 1,601,800 shares during the last quarter. Capital World Investors grew its stake in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after acquiring an additional 1,566,658 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock valued at $309,558,000 after purchasing an additional 1,107,998 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is owned by corporate insiders.

Danaher Price Performance

DHR stock traded down $7.16 during trading on Monday, reaching $197.69. The company's stock had a trading volume of 4,921,296 shares, compared to its average volume of 4,210,283. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70. The company's fifty day moving average is $196.05 and its 200-day moving average is $206.13. The company has a market capitalization of $141.48 billion, a P/E ratio of 38.39, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. On average, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher's payout ratio is currently 24.85%.

Analyst Ratings Changes

DHR has been the topic of several research reports. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday. The Goldman Sachs Group cut their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. TD Cowen boosted their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Finally, Wells Fargo & Company lowered their price objective on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $248.43.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.